Panel Discussion: What’s the New Path to the Next Generation of ADCs?

• Understanding how to migrate from non-selective ADC payloads
• Debating the right properties for a next-generation payload and linker: Can (or should?) any small molecule therapeutic be developed into an ADC?
• Debating the right strategy for dual payload ADCs
• Understanding ADC toxicity and developability for next generation conjugates 

Speakers:

Allan Jordan

Vice President - Oncology Drug Discovery

Sygnature Discovery

Joshua Greally

Scientific Business Development Manager

Sygnature Discovery